Page last updated: 2024-08-16

temozolomide and olaparib

temozolomide has been researched along with olaparib in 30 studies

Research

Studies (30)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (3.33)	29.6817
2010's	17 (56.67)	24.3611
2020's	12 (40.00)	2.80

Authors

Authors	Studies
Adcock, C; Boulter, R; Cockcroft, XL; Copsey, L; Cranston, A; Dillon, KJ; Drzewiecki, J; Garman, S; Gomez, S; Javaid, H; Kerrigan, F; Knights, C; Lau, A; Loh, VM; Martin, NM; Matthews, IT; Menear, KA; Moore, S; O'Connor, MJ; Smith, GC	1
Artali, R; Barbarino, M; Battistuzzi, G; Carollo, V; Dallavalle, S; De Paolis, F; Gallo, G; Giannini, G; Guglielmi, MB; Milazzo, FM; Vesci, L	1
Borghi, D; Busel, AA; Caprera, F; Casale, E; Ciomei, M; Cirla, A; Corti, E; D'Anello, M; Donati, D; Fasolini, M; Felder, ER; Forte, B; Galvani, A; Isacchi, A; Khvat, A; Krasavin, MY; Lupi, R; Montagnoli, A; Orsini, P; Papeo, G; Perego, R; Pesenti, E; Pezzetta, D; Posteri, H; Rainoldi, S; Riccardi-Sirtori, F; Scolaro, A; Sola, F; Zuccotto, F	1
Cao, R; Chen, X; Ji, M; Xu, B; Zhou, J; Zhu, Z	1
Cao, C; Chen, Y; Du, W; Wang, Y; Yang, J; Zhao, L; Zhou, P	1
Feng, Y; Gao, Y; Gong, W; Guo, Y; Huo, CX; Jiang, B; Kuang, X; Liu, X; Liu, Y; Luo, L; Lv, L; Peng, H; Qi, R; Qin, Z; Qiu, M; Ren, B; Su, D; Sun, X; Tang, T; Wang, F; Wang, H; Wang, L; Wang, X; Wang, Z; Wei, M; Wu, Y; Xu, D; Xu, H; Yan, H; Yu, F; Zhao, Y; Zhou, C; Zhu, Y	1
Chen, H; Cheung, F; Chow, JP; Li Lung, M; Man, WY; Mao, M; Nicholls, J; Poon, RY; Tsao, SW	1
Doroshow, JH; Huang, SY; Ji, J; Morris, J; Murai, J; Pommier, Y; Renaud, A; Takeda, S; Teicher, B; Zhang, Y	1
Akbari, MR; Aldape, KD; Denton-Schneider, BR; Hicks, D; Lee, J; McMullin, RP; Moulis, S; Narod, SA; Ramaswamy, S; Sgroi, DC; Singavarapu, R; Steeg, PS; Wittner, BS; Yang, C	1
Doroshow, JH; Ji, J; Morris, J; Murai, J; Pommier, Y; Takeda, S; Zhang, Y	1
Bahrami, A; Benavente, C; Bradley, C; Calabrese, C; Caufield, W; Dyer, MA; Freeman, BB; Gordon, B; Goshorn, R; Griffiths, LM; Hatfield, MJ; Karlström, Å; Loh, A; Miller, GM; Pappo, A; Potter, PM; Sablauer, A; Shelat, AA; Shirinifard, A; Snyder, SE; Stewart, E; Thiagarajan, S; Tsurkan, L; Twarog, NR; Wu, J	1
Engert, F; Fulda, S; Probst, M; Schneider, C; Weiβ, LM	1
Kondo, T; Miyamoto, M; Ohta, T; Watanabe, T; Yamamoto, Y; Yamasaki, H	1
de Stanchina, E; Desmeules, P; Gardner, EE; Lok, BH; Ni, A; Poirier, JT; Powell, SN; Rekhtman, N; Riaz, N; Rudin, CM; Schneeberger, VE; Teicher, BA	1
Bradbury, RH; Brown, H; Caldecott, KW; Cranston, AN; Evers, B; Jaspers, JE; Jones, L; Jonkers, J; Knights, C; Lau, A; Martin, NM; O'Connor, MJ; Odedra, R; Oplustil O'Connor, L; Pajic, M; Rottenberg, S; Rudge, D; Rulten, SL; Ting, A	1
Bautista, W; Ewend, MG; Frady, LN; Gilbert, MR; Kwintkiewicz, J; Liu, Y; Lu, Y; MacDonald, J; Moon, SI; Su, YT; Tech, K; Wu, J; Yang, C	1
Andre, B; Berro, DH; Brachet, PE; Capel, A; Castera, L; Clarisse, B; Coquan, E; Dugué, A; Emery, E; Geffrelot, J; Goardon, N; Grellard, JM; Kao, W; Lacroix, J; Lange, M; Leconte, A; Léger, A; Lelaidier, A; Lequesne, J; Lesueur, P; Stefan, D	1
Masuda, U; Matsumoto, A; Minegaki, T; Miyamoto, K; Moriyama, Y; Nishiguchi, K; Ota, K; Tanahashi, M; Tanaka, M; Tsujimoto, M; Wada, A; Yamamoto, A	1
Brunson, DC; Dershowitz, L; Do, D; Drapkin, BJ; Dubash, TD; Dyson, NJ; Fletcher, JA; Garcia, EG; Haber, DA; Hayes, MN; Hong, X; Iafrate, JA; Iftimia, NA; Karabacak, MN; Langenau, DM; Ligorio, M; Maheswaran, S; Marvin, DL; McCarthy, KM; Moore, JC; Myers, DT; Phat, S; Rawls, JF; Sgroi, DC; Tang, Q; Volorio, A; Welker, AM; Yan, C	1
Byers, LA; Pacheco, JM	1
Cahill, DP; Higuchi, F; Koerner, MVA; Nagashima, H; Ning, J; Wakimoto, H	1
Britt, N; Chudnovsky, Y; Duncan, D; Edgerly, C; Elvin, J; Erlich, RL; Gay, L; Gorelyshev, S; Hemmerich, A; Huang, RSP; Konovalov, A; Kram, DE; McCorkle, J; Miller, V; Ramkissoon, SH; Rankin, A; Ross, JS; Savateev, A; Severson, E; Trunin, Y; Valiakhmetova, A	1
Desar, IME; Fleuren, EDG; Flucke, UE; Hillebrandt-Roeffen, MHS; Mentzel, T; Shipley, J; van Bree, NFHN; van der Graaf, WTA; van Erp, AEM; van Houdt, L; Versleijen-Jonkers, YMH	1
Carruthers, R; Chalmers, AJ; Cruickshank, G; Dunn, L; Erridge, S; Godfrey, L; Halford, S; Hanna, C; Jackson, A; Jefferies, S; Kurian, KM; McBain, C; McCormick, A; Pittman, M; Sleigh, R; Strathdee, K; Watts, C; Williams, K	1
Bindra, RS	1
Alpert, EJ; Brunson, DC; Cobbold, M; Do, D; Drapkin, BJ; Dyson, NJ; Iyer, S; Langenau, DM; Maus, MV; McCarthy, KM; Millar, DG; Moore, JC; Qin, Q; Rawls, JF; Scarfò, I; Stanzione, M; Veloso, A; Wei, Y; Yan, C; Yang, Q; Zhang, S	1
Cacace, A; Dumon, E; Frédérick, R; Grasso, D; Hamelin, L; Lefranc, F; Rossignol, R; Sboarina, M; Sonveaux, E; Sonveaux, P; Thabault, L; Vazeille, T; Zampieri, LX	1
Hirota, K; Ibrahim, MA; Masutani, M; Ooka, M; Sasanuma, H; Shimizu, N; Takeda, S; Tsuda, M; Yamada, K; Yamada, S	1
Drapkin, BJ; Dyson, NJ; Farago, AF; Hadden, MK; LaSalle, TJ; Lawrence, MS; Myers, DT; Phat, S; Sade-Feldman, M; Simoneau, A; Stanzione, M; Wise, JF; Wong, E; Zhong, J; Zou, L	1
Allred, JB; Attia, S; Boikos, SA; Bose, S; Bui, N; Burgess, MA; Chen, JL; Chen, L; Close, JL; Cote, GM; D'Andrea, A; Das, B; Gano, K; George, S; Ingham, M; Ivy, SP; Kochupurakkal, B; Marino-Enriquez, A; Schwartz, GK; Seetharam, M; Shapiro, GI; Thaker, PH	1

Trials

3 trial(s) available for temozolomide and olaparib

Article	Year
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC cancer, 2019, Mar-04, Volume: 19, Issue:1 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiotherapy, Intensity-Modulated; Temozolomide	2019
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-oncology, 2020, 12-18, Volume: 22, Issue:12 Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Glioblastoma; Humans; Mice; Phthalazines; Piperazines; Rats; Temozolomide	2020
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 09-01, Volume: 41, Issue:25 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Female; Humans; Leiomyosarcoma; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Phthalazines; Temozolomide; Uterine Neoplasms	2023

Other Studies

27 other study(ies) available for temozolomide and olaparib

Article	Year
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. Journal of medicinal chemistry, 2008, Oct-23, Volume: 51, Issue:20 Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Dogs; Enzyme Inhibitors; Humans; Mice; Molecular Structure; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Structure-Activity Relationship	2008
Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold. Bioorganic & medicinal chemistry letters, 2014, Jan-15, Volume: 24, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Mice; Mice, SCID; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolinones; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2014
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. Journal of medicinal chemistry, 2015, Sep-10, Volume: 58, Issue:17 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Proliferation; Dacarbazine; Drug Screening Assays, Antitumor; Female; Heterografts; High-Throughput Screening Assays; Humans; Isoindoles; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Models, Molecular; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Rats, Sprague-Dawley; Structure-Activity Relationship; Temozolomide; Triple Negative Breast Neoplasms	2015
Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity. European journal of medicinal chemistry, 2017, May-26, Volume: 132 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line; Crystallography, X-Ray; Dacarbazine; Drug Design; Drug Synergism; Enzyme Inhibitors; Heterografts; Inhibitory Concentration 50; Poly (ADP-Ribose) Polymerase-1; Protein Binding; Structure-Activity Relationship; Temozolomide	2017
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. Journal of medicinal chemistry, 2020, 10-08, Volume: 63, Issue:19 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Ligands; Mice; Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Proteolysis	2020
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development. Journal of medicinal chemistry, 2020, 12-24, Volume: 63, Issue:24 Topics: Animals; Binding Sites; Carbazoles; Cell Proliferation; Dogs; Female; Fluorenes; Half-Life; Humans; Indoles; Isoenzymes; Mice; Microsomes; Molecular Docking Simulation; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2020
PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy. Molecular cancer therapeutics, 2013, Volume: 12, Issue:11 Topics: Adult; Aged; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Experimental; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tissue Array Analysis; Xenograft Model Antitumor Assays	2013
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Molecular cancer therapeutics, 2014, Volume: 13, Issue:2 Topics: Adenosine Triphosphate; Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorescence Polarization; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Methyl Methanesulfonate; Molecular Structure; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Stereoisomerism; Temozolomide	2014
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast cancer research : BCR, 2014, Mar-14, Volume: 16, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; BRCA1 Protein; Breast Neoplasms; Cell Line; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Mutational Analysis; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Oligonucleotide Array Sequence Analysis; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Receptor, ErbB-2; Temozolomide; Transcriptome	2014
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. The Journal of pharmacology and experimental therapeutics, 2014, Volume: 349, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Chickens; Dacarbazine; DNA Damage; DNA Repair; Drug Synergism; Enzyme Inhibitors; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide	2014
Targeting the DNA repair pathway in Ewing sarcoma. Cell reports, 2014, Nov-06, Volume: 9, Issue:3 Topics: Animals; Benzimidazoles; Camptothecin; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Enzyme Inhibitors; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sarcoma, Ewing; Temozolomide; Xenograft Model Antitumor Assays	2014
PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. Molecular cancer therapeutics, 2015, Volume: 14, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dacarbazine; Dactinomycin; Doxorubicin; Drug Synergism; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Ifosfamide; Metabolic Networks and Pathways; Mitochondria; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Sarcoma, Ewing; Temozolomide; Vincristine	2015
Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor. Genes to cells : devoted to molecular & cellular mechanisms, 2016, Volume: 21, Issue:8 Topics: Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Damage; DNA Repair; Etoposide; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation, Ionizing; Recombinational DNA Repair; Sarcoma, Synovial; Temozolomide; Topoisomerase II Inhibitors	2016
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Jan-15, Volume: 23, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genomics; Humans; Indoles; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Small Cell Lung Carcinoma; Temozolomide; Xenograft Model Antitumor Assays	2017
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. Cancer research, 2016, 10-15, Volume: 76, Issue:20 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair; Drug Discovery; Genes, BRCA1; Humans; Mice; Neoplasms, Experimental; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Temozolomide; Xenograft Model Antitumor Assays	2016
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. Cancer research, 2017, 04-01, Volume: 77, Issue:7 Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Temozolomide	2017
Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines. Anticancer research, 2019, Volume: 39, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Esophageal Squamous Cell Carcinoma; Histones; Humans; Irinotecan; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide	2019
Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. Cell, 2019, 06-13, Volume: 177, Issue:7 Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Female; Heterografts; Humans; K562 Cells; Male; Muscle Neoplasms; Neoplasm Transplantation; Phthalazines; Piperazines; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays; Zebrafish	2019
Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates? Cancer discovery, 2019, Volume: 9, Issue:10 Topics: Animals; Biomarkers; Cell Line, Tumor; Heterografts; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Xenograft Model Antitumor Assays	2019
Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 04-01, Volume: 26, Issue:7 Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Mismatch Repair; DNA Repair; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Mice; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Xenograft Model Antitumor Assays	2020
Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. The oncologist, 2020, Volume: 25, Issue:2 Topics: Antineoplastic Agents; Child; Child, Preschool; Female; Glioblastoma; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Temozolomide	2020
Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:7 Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Child; Desmoplastic Small Round Cell Tumor; Disease Models, Animal; Drug Synergism; Female; Gene Expression; Humans; Male; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Xenograft Model Antitumor Assays; Young Adult	2020
Penetrating the brain tumor space with DNA damage response inhibitors. Neuro-oncology, 2020, 12-18, Volume: 22, Issue:12 Topics: Brain Neoplasms; DNA Damage; Glioblastoma; Humans; Phthalazines; Piperazines; Temozolomide	2020
Single-cell imaging of T cell immunotherapy responses in vivo. The Journal of experimental medicine, 2021, 10-04, Volume: 218, Issue:10 Topics: Adolescent; Adult; Animals; Animals, Genetically Modified; Child; Child, Preschool; DNA-Binding Proteins; ErbB Receptors; Female; Humans; Immunotherapy; Immunotherapy, Adoptive; Interleukin Receptor Common gamma Subunit; Male; Mice, Inbred Strains; Phthalazines; Piperazines; Rhabdomyosarcoma; Single-Cell Analysis; T-Lymphocytes; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zebrafish; Zebrafish Proteins	2021
Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells. International journal of molecular sciences, 2021, Nov-03, Volume: 22, Issue:21 Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Tumor Cells, Cultured	2021
XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. Genes to cells : devoted to molecular & cellular mechanisms, 2022, Volume: 27, Issue:5 Topics: Adenosine Diphosphate Ribose; Alkylating Agents; DNA; DNA Damage; DNA Repair; Methyl Methanesulfonate; Phthalazines; Piperazines; Poisons; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide	2022
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer. Science advances, 2022, 05-13, Volume: 8, Issue:19 Topics: Cell Line, Tumor; DNA; DNA Damage; DNA Replication; Humans; Lung Neoplasms; Phthalazines; Piperazines; Small Cell Lung Carcinoma; Temozolomide	2022